Details

Subject(s)

• Fungal metabolites [Browse]
• Fungi—Therapeutic use [Browse]

Editor

• Deshmukh, Sunil Kumar [Browse]
• Takahashi, Jacqueline Aparecida [Browse]
• Saxena, Sanjai [Browse]

Bibliographic references

Includes bibliographical references.

Source of description

• Description based on publisher supplied metadata and other sources.
• Description based on print version record.

Contents

• Intro
• Preface
• Contents
• Editors and Contributors
• Part I: Bioactive Compounds from Endophytic Fungi
• Chapter 1: Recent Advances in Pharmaceutically Important Compounds from Endophytic Fungi
• 1 Introduction
• 2 Biomes, Regions, and Plant Families
• 3 Handling Endophytic Fungi
• 4 Innovative Pharmacological Targets for Bioactive Fungal Metabolites
• 5 Promising Endophytic Fungi Metabolites Recently Described
• 6 Developments Related to Bioactive Metabolites from Endophyte Fungi
• 7 Perspectives
• References
• Chapter 2: Recent Advances in Anti-Infective Compounds Produced by Endophytic Fungi
• 2 Role of Endophytic Research with Respect to Drug Discovery
• 3 Antibacterial Metabolites
• 3.1 Antimycobacterial Compounds from Endophytes
• 4 Antifungal Metabolites
• 5 Antiviral Metabolites
• 6 Antiprotozoal Metabolites
• 6.1 Antimalarial Metabolites
• 6.2 Anti-Leishmanial Metabolites
• 6.3 Anti-Trypanosomal Metabolites
• 7 Future Prospects and Challenges
• Chapter 3: Fungal Endophytes: An Accessible Natural Repository for Discovery of Bioactive Compounds
• 1 Endophytic Natural Products (ENPs): An Introduction
• 1.1 Endophytes as a Treasure Hunt for ENPs
• 1.2 Polyketides, an Important Class of Bioactive ENPs
• 1.3 Small Peptides as Bioactive ENPs
• 2 ENPs with Anticancer Potential
• 3 ENPs with Antimicrobial Potential
• 4 Molecular Crosstalk Underlying ENPs Production
• 5 Conclusion
• Part II: Endolichenic Fungi: a Source of New Chemical Entities
• Chapter 4: Endolichenic Fungi as a Source of Pharmaceutically Active Compounds
• 2 Pharmaceutically Active Compounds Isolated from Endolichenic Fungi
• 2.1 Cytotoxic Compounds Isolated from Endolichenic Fungi
• 2.2 Antifungal Compounds Isolated from Endolichenic Fungi.
• 2.3 Antioxidant Compounds Isolated from Endolichenic Fungi
• 2.4 Antibacterial Compounds Isolated from Endolichenic Fungi
• 2.5 Antiviral Compounds Isolated from Endolichenic Fungi
• 2.6 Anti-Inflammatory Compounds Isolated from Endolichenic Fungi
• 3 Classification of Bioactive Compounds According to Selected Taxa of Their Endolichenic Fungi
• 4 Summary Statement
• Chapter 5: Endolichenic Fungi, an Emerging Source of Bioactive Compounds: A Pharmaceutical Perspective
• 2 Anticancer Compounds
• 3 Anti-Microbial Compounds
• 3.1 Antibacterial Compounds
• 3.2 Antifungal Compounds
• 4 Anti-Inflammatory Compounds
• 5 Anti-Alzheimer Compounds
• 6 Antioxidant Compounds
• 7 AChE Inhibitors
• 8 Phytotoxic Compounds
• 9 Antithrombotic Compounds
• 10 Conclusion
• Part III: Marine Fungi as a Source of Medicinal Compounds
• Chapter 6: Antibiofilm Metabolites from Sponge-Derived Aspergillus, Penicillium, and Fusarium for the Antibiotic Pipeline
• 1.1 Antibiofilm Mechanism of Action Versus Antibiotic Resistance
• 1.2 Marine Sponge Symbionts as a Potential Source of Antimicrobials
• 2 Secondary Metabolites and New Potential Antibiotics
• 2.1 Antimicrobials
• 2.1.1 Aspergillus Antimicrobial Metabolites
• 2.1.2 Penicillium Antimicrobial Metabolites
• 2.1.3 Fusarium Antimicrobial Metabolites
• 2.2 Antibiofilms
• 2.2.1 Aspergillus Antibiofilm Metabolites
• 2.2.2 Penicillium Antibiofilm Metabolites
• 2.2.3 Fusarium Antibiofilm Metabolites
• 3 Global Distribution of Antibacterial Sponge-Derived Fungal Metabolites
• 3.1 Antibacterial
• 3.2 Antibacterial Sponge-Derived Penicillium Metabolites
• 3.3 Antibacterial Sponge-Derived Fusarium Metabolites
• 4 Bioprospecting Antibiofilm Metabolites
• 4.1 What Is Bioprospecting?
• 4.2 Methods Used for Bioprospecting.
• 5 Summary and Conclusion
• Untitled
• Chapter 7: Marine Fungi as a Bioresource of Medicinal Entities
• 2 Sources of Marine Fungi
• 2.1 Plant Sources
• 2.1.1 Marine Algae and Seaweeds
• 2.2 Animal Sources
• 2.2.1 Sponges
• 2.2.2 Corals
• 2.2.3 Sea Urchins
• 2.2.4 Marine Vertebrates: Fish
• 2.3 Mangrove Soil
• 2.4 Marine Sediment
• 3 How Can Marine Fungal Compounds Serve as Novel Drugs?
• 4 Challenges and Future Aspects
• 4.1 Untapping the Potential of Marine Fungi
• 4.2 Quantity of Secondary Metabolites Produced.
• 4.3 Understanding of Complete Secondary Metabolites Synthesis Pathway in Marine Fungi
• 4.4 Sustainable Drug Delivery
• 4.5 Industrial Transition and Commercialization
• 5 Conclusions
• Chapter 8: Natural Bioactive Products from Marine Fungi Against Bacterial Infection
• 2 Fungal Secondary Metabolites Biosynthetic Pathway
• 3 Bioactive Compounds Derived from Marine Fungi
• 4 Marine-Derived Fungi Effective Against Different Bacterial Pathogens
• 4.1 Marine-Derived Compounds Effective to Gram-Positive Bacterial Pathogens
• 4.2 Marine-Derived Fungal Compounds Effective Against Gram-Negative Bacteria
• 4.3 Broad-Spectrum Antimicrobial Effect of Marine-Derived Fungal Secondary Metabolites
• 4.4 Marine-Derived Fungal Secondary Metabolites Effective Against Multidrug Resistant Bacterial Strains
• 6 Future Prospects
• Part IV: Fungi as a Bioresource of Pharmacologically Active Agents
• Chapter 9: Penicillium: A Treasure Trove for Antimycobacterial and Antioxidant Metabolites
• 2 Antimycobacterial Activity of Penicillium
• 3 Antioxidant Activity of Penicillium
• 4 Biotechnological Interventions in Penicillium for Enhanced Metabolite Production
• 4.1 Antimycobacterial Potential
• 4.2 Antioxidant Potential.
• Chapter 10: Metabolites from Fungi: A Promising Source of Lead Compounds Against Cancer
• 1 Historical Overview: Discovery of Anticancer Drugs from Fungi
• 2 Promising Fungal Metabolites and Derivatives with Anticancer Effects
• 2.1 Edible and Medicinal Mushrooms
• 2.2 Endophytic Fungi
• 2.3 Fungi from Other Biomes
• 3 Future Perspectives: What´s Next in the Pathway of Anticancer Drug Discovery from Fungal Compounds
• 4 Final Considerations
• Chapter 11: Edible Mushrooms Substances as Natural Prevention in Autoimmunological Diseases
• 2 Primary Metabolites: Significant Developments
• 2.1 Carbohydrates
• 2.2 Amino Acids and Proteins
• 2.3 Glycoproteins: Lectins
• 2.4 Lipids
• 3 Secondary Metabolites: Significant Developments
• 3.1 Phenolic Compounds
• 3.2 Indole Compounds
• 3.3 Vitamins
• 3.4 Isoprenoids
• 3.5 Bioelements
• 4 Conclusions
• Chapter 12: New Antifungal Drugs: Discovery and Therapeutic Potential
• 2 Target Fungal Cell Wall and Membrane Synthesis
• 2.1 Fosmanogepix/Manogepix (A Novel Gwt1 Enzyme Inhibitor, AMPLYX)
• 2.1.1 Mechanism of Action
• 2.1.2 Spectrum of Activity
• 2.1.3 Mouse Model Studies
• 2.1.4 Clinical Studies
• 2.2 Ibrexafungerp (An Enfumafungin Derivative, Glucan Synthase Inhibitor, Scynexis)
• 2.2.1 Mechanism of Action
• 2.2.2 Spectrum of Activity/in Vivo Susceptibility Data
• 2.2.3 Clinical Development
• 2.3 Rezafungin (Second-Generation Echinocandins, CIDARA)
• 2.3.1 Mechanism of Action
• 2.3.2 Spectrum of Activity/In Vivo Susceptibility Data
• 2.3.3 Clinical Development
• 2.4 Encochleated Amphotericin B (MAT2203, CAmB-MATINAS, Cell Membrane Inhibitor)
• 2.4.1 Mechanism of Action
• 2.4.2 Spectrum of Activity/In Vivo Susceptibility Data
• 2.4.3 Clinical Development
• 3 Tetrazole Inhibitors.
• 3.1 Oteseconazole (VT-1161), VT-1598, VT-1129 (Mycovia, Novel Tetrazole-Specific Cyp51 Inhibitors)
• 3.1.1 Mechanism of Action and Spectrum of Activity/In Vivo Susceptibility Data
• 3.1.2 Clinical Development
• 3.2 Opelconazole (PC945, Pulmocide, Novel Tetrazole-Specific Cyp51 Inhibitors)
• 3.2.1 Mechanism of Action
• 3.2.2 Spectrum of Activity/In Vivo Susceptibility Data
• 3.2.3 Clinical Development
• 4 Target Nucleic Acid Metabolism
• 4.1 Olorofim (F2G, LTD, a Novel Dihydroorotate Dehydrogenase Enzyme Inhibitor)
• 4.1.1 Mechanism of Action
• 4.1.2 Spectrum of Activity/In Vivo Susceptibility Data
• 4.1.3 Clinical Data
• 5 Final Evaluation
• Chapter 13: Fungal Enzyme Inhibitors: Potent Repository of Lead Compounds to Curb Cancer
• 1.1 Cancer
• 1.2 Rationale of Selecting Enzyme Inhibitors for Anticancer Therapy
• 2 Selective Enzyme Targets for Discovering Endophytic Fungal Inhibitors
• 2.1 DNA Topoisomerases
• 2.2 Telomerase
• 2.3 Angiotensin-Converting Enzyme (ACE)
• 2.4 Histone Deacetylase (HDAC)
• 2.5 DNA Polymerase
• 2.6 Methionine Aminopeptidase 2 (Met AP-2)
• 2.7 Caspase-1
• 2.8 Cyclooxygenase (COX)
• 2.9 Phosphatidylinositol 3′ Kinases (PI3Ks)
• 3 Concluding Remarks
• Chapter 14: Bioactive Metabolites from Fungi with Anti-Inflammatory and Antithrombotic Properties: Current Status and Future P...
• 2 Fungi as Sustainable Sources for Bioactive Compounds of Natural Origin
• 3 Fungi Bioactive Metabolites with Anti-Inflammatory and Antithrombotic Properties as Candidates for the Development of Supple...
• 3.1 Fungi-Derived Vitamins and Bioactive Carotenoid-Based Colored Pigments
• 3.2 Fungi-Derived Classic and Complex Bioactive Phenolic Compounds/Pigments with Anti-Inflammatory and Antithrombotic Properti.
• 3.3 Fungi Lipid Bioactives with Anti-Inflammatory and Antithrombotic Properties.

Show 185 more Contents items

ISBN

981-9956-96-X

Statement on language in description

Princeton University Library aims to describe library materials in a manner that is respectful to the individuals and communities who create, use, and are represented in the collections we manage. Read more...